De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC

Investigators retrospectively recruited the triple negative breast cancer patients with clinical stage T2 and above and/or lymph node positive who received neoadjuvant therapy (TCb-AC combined with immunotherapy, TCb combined with immunotherapy, or TCb chemotherapy only) admitted to the center from January 1, 2019 to November 31, 2024. Patients of the same type from December 1, 2024 to December 31, 2028 were prospectively included. The efficacy and safety of different treatment regimens were compared.

Inclusion criteria

• Patients with triple negative breast cancer diagnosed by biopsy in Peking University People's Hospital;
• The clinical stage was stage II or stage III (i.e. T2 and above, and/or lymph node positive, without distant organ metastasis);
• Received treatment in our hospital and had hospitalization records;
• Has signed and agreed to participate in the PKUPH breast disease cohort study.

Exclusion criteria

• Lack of clinical and pathological data (such as imaging data and pathological data);
• Patients with metastatic breast cancer or bilateral breast cancer;
• At the same time, they received anti-tumor therapy in other clinical trials, including endocrine therapy and targeted therapy;
• Receiving other regimens besides the established neoadjuvant regimens

Primary end point: pathology complete response

Inclusion criteria

• 1) Patients with triple negative breast cancer diagnosed by biopsy in Peking University People's Hospital;
• 2) The clinical stage was stage II or stage III (i.e. T2 and above, and/or lymph node positive, without distant organ metastasis);
• 3) Received treatment in our hospital and had hospitalization records;
• 4) Has signed and agreed to participate in the PKUPH breast disease cohort study.

Exclusion criteria

• 1) Lack of clinical and pathological data (such as imaging data and pathological data);
• 2) Patients with metastatic breast cancer or bilateral breast cancer;
• 3) At the same time, they received anti-tumor therapy in other clinical trials, including endocrine therapy and targeted therapy;
• 4) Receiving other regimens besides the established neoadjuvant regimens